The expression levels of BCL2, a gene that cooperates with pro-proliferative signal to support BC initiation and progression and therapeutic resistance [34], were dramatically decreased (14.6-fold) upon DLL1 downregulation. This evidence concerns the gene DLL1 and breast cancer.